NCT07795762Not yet recruitingPhase 1
Eplerenone and IOP in Healthy Adults
Effect of Short-Term Oral Eplerenone on Intraocular Pressure in Healthy Adult Volunteers: A Randomized, Double-Masked, Placebo-Controlled Crossover Study
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
The goal of this clinical trial is to determine whether eplerenone lowers eye pressure in healthy adults. Eplerenone is a medication approved by the U.S. Food and Drug Administration for other medical conditions. Researchers will compare eplerenone with placebo (a substance containing no active drug) to determine whether eplerenone affects intraocular pressure (IOP). Participants will receive both eplerenone and placebo during different study periods and will have their eye pressure measured throughout the study. Blood pressure, kidney function, and potassium levels will also be monitored for safety.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 26 Aug 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- University of Florida
- Diseases
- High blood pressure
- NCT number
- NCT07795762
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 30
- From 1 Oct 2026 to the primary completion date, 1 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of topical or systemic steroids
- Concomitant use of strong CYP3A inhibitors, including clarithromycin, erythromycin, ketoconazole, itraconazole, fluconazole, verapamil, diltiazem, or ritonavir
- Use of medications known to affect intraocular pressure, including topical prostaglandin analogs, topical or systemic beta-blockers, topical alpha-2 agonists, topical or systemic carbonic anhydrase inhibitors, topical Rho-kinase inhibitors, or topical parasympathomimetics
Other illness
- Renal disease or hyperkalemia
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Adults aged 18-50 years
- No history of glaucoma or ocular hypertension
- Baseline intraocular pressure between 10-21 mmHg
- Serum creatinine ≤1.3 mg/dL and serum potassium \<4.3 mmol/L
- Systolic blood pressure \>110 mmHg
Age in the registry: 18 years to 50 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UF Health Eye Center - The Oaks Coordinator of this site? Confirm its status | Gainesville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.